Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS SUMMARY: Astra Up On Covid Vaccine Approval In UK

Wed, 30th Dec 2020 10:39

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Wednesday.

----------

FTSE 100 - WINNERS

----------

AstraZeneca, up 0.8%. The Anglo-Swedish drug manufacturer said its Covid-19 vaccine developed in partnership with Oxford University has been approved by the UK Medicines & Healthcare products Regulatory Agency for emergency supply in the country. Astra said the first doses will be released Wednesday in order for vaccinations to start early in the new year. The vaccine has been approved for the immunization of individuals aged 18 and over, with the authorisation recommending two doses administered with an interval of four to 12 weeks. The AstraZeneca vaccine is the second to be approved in the UK. The Pfizer Inc-BioNTech SE vaccine was approved earlier in December.

----------

FTSE 250 - WINNERS

----------

Energean, up 2.2%. The company reached an agreement with Kerogen Investments, an affiliate of Kerogen Capital, for the acquisition of Kerogen's 30% shareholding in Energean Israel. This will result in Energean owning 100% of the Israeli business. The total consideration will be between USD380 million and USD405 million, the Mediterranean-focus gas exploration and production company said. Energean said the acquisition adds 2P reserves of 29.5 billion cubic metres of gas and 30 million barrels of liquids, representing 219 million barrels of oil equivalent in total, to the company. Taking a 100% interest in Energean Israel will enable Energean to fully control its capital structure, it said, enhancing its ability to maximise total shareholder returns.

----------

OTHER MAIN MARKET AND AIM - WINNERS

----------

iEnergizer, up 15%. The Guernsey-based business process outsourcing firm said it has entered into a credit agreement for a five-year senior secured term loan facility of USD165 million, which includes a USD15 million revolving credit facility. The company said the facility - which has an interest rate of 3.75% plus the London Inter-bank Offered Rate - has been secured on significantly more attractive commercial terms than the existing debt facility which it is replacing, iEnergizer said. This had a minimum 7.0% interest rate. The new facility does not restrict dividend payments, subject to maintenance of facility covenants, so iEnergizer will maintain its existing dividend policy. iEnergizer said the facility was put in place to increase debt use within the company's overall capital structure, with existing debt facilities having been substantially repaid. The additional financing will be used to return cash to shareholders.

----------

Bluejay Mining, up 4.0%. The exploration and development resource company said it has received a research and development rebate of GBP264,775 gross in cash from the UK government for scientific research carried out on the Dundas titanium project in Greenland over the last two field seasons. The company said the rebate was for eligible expenses incurred at the project during 2018 and 2019. Geology Manager Eric Sondergaard said: "It is very pleasing to receive this R&D cash rebate, a significant sum that will contribute to future activities across our portfolio. Bluejay will continue to evaluate future strategic R&D credit opportunities, specifically as it advances its exploration planning for 2021 at its various projects."

----------

OTHER MAIN MARKET AND AIM - LOSERS

----------

Uru Metals, down 12%. The exploration & development company posted a widened loss for its first half due to higher costs and the settlement of debts. For the six months ended September, the firm posted a total loss of USD1.6 million, widened from USD230,000 the year prior, as administrative expenses rose to USD302,000 from USD263,000 and the company recognised a loss of USD1.5 million on the settlement of debts. Looking ahead, Chair Jay Vieira said: "URU continues to believe that the long-term fundamentals of the base minerals industries remain positive and will be working hard in the coming year to unlock the value of our projects for our shareholders. The company maintains its core strategy to develop its nickel assets, as the board anticipates growing demand and price appreciation for nickel in the short to medium term."

----------

Kodal Minerals, down 11%. The mineral exploration & development company said it has received a conversion notice in relation to its USD1.5 million unsecured convertible loan agreement with Riverfort Global Opportunities PCC and YA II PN. The company said the investors have elected to convert USD150,810 into 176.2 million new shares at a price of 0.06340 pence per share.

----------

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.